Egrifta (tesamorelin) is formed with growth hormone-releasing issue (GRF).
Egrifta is employed to scale back excess fat round the abdomen that’s caused by taking sure HIV medications. This condition is additionally known as lipodystrophy (LYE-poe-DIS-troe-fee).
Egrifta isn’t a weight-loss medication and will not be accustomed treat fat.
Submit your review
Get emergency medical help if you have any of these signs of an allergic reaction to Egrifta: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using Egrifta and call your doctor at once if you have a serious side effect such as:
swelling in your hands, ankles, or feet;
pain or stiffness in your muscles or joints;
pain in your arms or legs;
wrist pain or numbness;
numbness or tingling in your hands or fingers;
pounding heartbeats or fluttering in your chest;
high blood sugar (increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, weight loss);
Less serious Egrifta side effects may include:
depressed mood, sleep problems (insomnia);
mild rash or itching;
nausea, vomiting, upset stomach;
pain, redness, itching, swelling, bruising, bleeding, or other irritation where the injection was given;
The recommended dose of EGRIFTA® is 2 mg injected subcutaneously once a day. The recommended injection site is the abdomen. Injection sites should be rotated to different areas of the abdomen. Do not inject into scar tissue, bruises or the navel.